RICHARD GAYNOR
CIK 1741284 · President of R&D · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.49M
Companies
4
Total Filings
37
Lifetime Open-Market Net
-$156.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZLAB | Director | 80,737 | $20.88 | $1.69M | -$70.6K | 9 | 2026-07-06 |
| ALKS | Director | 37,226 | $48.37 | $1.80M | $0 | 16 | 2026-05-22 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 3 | 2022-06-16 |
| Neon Therapeutics, Inc. (NTGN) Delisted | President of R&D | 0 | — | — | -$85.4K | 7 | 2020-05-06 |
Recent Filings · Page 3 of 4
37 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-16 | ALKS | Mixed | +6,890 | -$18.9K | EDGAR |
| 2021-12-03 | ALKS | Mixed | +4,239 | -$29.6K | EDGAR |
| 2021-11-22 | ZLAB | Grant (A) | +8,912 | $0 | EDGAR |
| 2021-06-16 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | ALKS | Mixed | +4,700 | -$30.8K | EDGAR |
| 2020-12-04 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2020-05-22 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2020-05-06 | Neon Therapeutics, Inc. (NTGN) Delisted | Disp (D) | −210,410 | $0 | EDGAR |
| 2020-03-17 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.